WallStreetZenWallStreetZen

NASDAQ: BEAT
Heartbeam Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BEAT

Based on 2 analysts offering 12 month price targets for Heartbeam Inc

Min Forecast
$5.50+59.88%
Avg Forecast
$6.75+96.22%
Max Forecast
$8.00+132.56%

Should I buy or sell BEAT stock?

Based on 2 analysts offering ratings for Heartbeam Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BEAT stock forecasts and price targets.

BEAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-11
lockedlocked$00.00+00.00%2025-12-10

1 of 1

Forecast return on equity

Is BEAT forecast to generate an efficient return?

Company
-4,050.09%
Industry
12.51%
Market
339.58%
BEAT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BEAT forecast to generate an efficient return on assets?

Company
-571.74%
Industry
12.99%
BEAT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BEAT earnings per share forecast

What is BEAT's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.64
Avg 2 year Forecast
-$0.59
Avg 3 year Forecast
-$0.48

BEAT revenue forecast

What is BEAT's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$2.1M
Avg 3 year Forecast
$12.0M

BEAT vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
BEAT$3.44$6.75+96.22%Strong Buy
CCLD$3.21N/AN/A
EUDA$2.40N/AN/A
AMWL$4.70$7.50+59.57%Buy
LFMD$3.42$9.63+181.43%Strong Buy
View Top Health Information Service Stocks

Heartbeam Stock Forecast FAQ

Is Heartbeam Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BEAT) stock is to Strong Buy BEAT stock.

Out of 2 analysts, 1 (50%) are recommending BEAT as a Strong Buy, 1 (50%) are recommending BEAT as a Buy, 0 (0%) are recommending BEAT as a Hold, 0 (0%) are recommending BEAT as a Sell, and 0 (0%) are recommending BEAT as a Strong Sell.

If you're new to stock investing, here's how to buy Heartbeam stock.

What is BEAT's earnings growth forecast for 2025-2027?

(NASDAQ: BEAT) Heartbeam's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 44.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.63%.

Heartbeam's earnings in 2025 is -$20,620,000.On average, 5 Wall Street analysts forecast BEAT's earnings for 2025 to be -$22,185,099, with the lowest BEAT earnings forecast at -$21,365,342, and the highest BEAT earnings forecast at -$22,784,417. On average, 4 Wall Street analysts forecast BEAT's earnings for 2026 to be -$20,376,812, with the lowest BEAT earnings forecast at -$21,940,550, and the highest BEAT earnings forecast at -$18,444,528.

In 2027, BEAT is forecast to generate -$16,443,357 in earnings, with the lowest earnings forecast at -$16,067,922 and the highest earnings forecast at -$16,636,241.

What is BEAT's revenue growth forecast for 2025-2027?

(NASDAQ: BEAT) Heartbeam's forecast annual revenue growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 9.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.25%.

Heartbeam's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast BEAT's revenue for 2025 to be $0, with the lowest BEAT revenue forecast at $0, and the highest BEAT revenue forecast at $0. On average, 4 Wall Street analysts forecast BEAT's revenue for 2026 to be $72,917,023, with the lowest BEAT revenue forecast at $54,007,507, and the highest BEAT revenue forecast at $92,239,862.

In 2027, BEAT is forecast to generate $414,562,724 in revenue, with the lowest revenue forecast at $398,305,363 and the highest revenue forecast at $426,755,746.

What is BEAT's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BEAT) forecast ROA is -571.74%, which is lower than the forecast US Health Information Services industry average of 12.99%.

What is BEAT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BEAT price target, the average BEAT price target is $6.75, with the highest BEAT stock price forecast at $8.00 and the lowest BEAT stock price forecast at $5.50.

On average, Wall Street analysts predict that Heartbeam's share price could reach $6.75 by Dec 11, 2026. The average Heartbeam stock price prediction forecasts a potential upside of 96.22% from the current BEAT share price of $3.44.

What is BEAT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BEAT) Heartbeam's current Earnings Per Share (EPS) is -$0.66. On average, analysts forecast that BEAT's EPS will be -$0.64 for 2025, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.66. On average, analysts forecast that BEAT's EPS will be -$0.59 for 2026, with the lowest EPS forecast at -$0.64, and the highest EPS forecast at -$0.54. In 2027, BEAT's EPS is forecast to hit -$0.48 (min: -$0.47, max: -$0.48).

What is BEAT's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BEAT) forecast ROE is -4,050.09%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.